Hofseth Biocare ASA
Christoph Baldegger, primary insider and member of the Board of Directors in Hofseth BioCare ASA ("HBC"), has today purchased 70,000 shares in HBC at an average price of NOK 9.294 per share.
As a result of the transaction, Mr. Baldegger holds 650,000 shares in HBC, equal to 0.18 % of the outstanding shares.
This information is subject of the disclosure requirements pursuant to sections 4-2 and 5-12 of the Norwegian Securities Trading Act.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Ecorobotix SA8.11.2025 12:15:00 CET | Press release
Ecorobotix Showcases World-First AI Capability for Safe, Targeted Use of Non-Selective Contact Herbicides at Agritechnica
IOT Squared8.11.2025 11:00:00 CET | Press release
Saudi “Emerge” Emergency and Crisis Resilience Platform Named Among the World’s Best Smart City Solutions in the 2025 Smart City Awards
Novo Nordisk A/S8.11.2025 09:18:56 CET | Press release
Novo Nordisk will not increase its proposal to acquire Metsera, Inc.
Teva Pharmaceutical Industries Ltd8.11.2025 00:00:00 CET | Press release
AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in Involuntary Movements and Activities of Daily Living
Columbus A/S7.11.2025 23:46:30 CET | Press release
Notification of transactions in Columbus A/S shares and related securities by persons discharging managerial responsibilities and persons closely associated with them
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom